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ABSTRACT 
BACKGROUND:  Generic fixed-dose combination (FDC) antiretroviral therapy 
(ART) has been widely used in resource-limited settings. Treatment based on these 
combinations provide low pill burden and are less expensive. 
OBJECT IVE:  The aim of this study was to determine the long-term effectiveness 
and metabolic omplications of a generic FDC of stavudine (d4T)/lamivudine (3TC)/ 
nevirapine (NVP), among ART-naive HIV-infected patients. 
METHODS:  A prospective study was conducted among patients who were initiated 
on d4T/3TC/NVP between November 2004 and March 2005. Plasma HIV-1 RNA, 
CD4 and alanine transaminase w re assessed every 12 weeks. Fasting plasma glucose 
(FPG) and lipid profile were determined at 96 weeks. Adverse events and genotypic 
drug resistance were recorded. The primary outcome of interest was the proportion of 
patients who achieved plasma HIV-1 RNA <50 copies/mL after 96 weeks of ART and 
analyzed by intent-to-treat (ITT) and on-treatment (OT) populations. 
RESULTS:  There were 140 patients (mean [SD] age, 35.7 [7.6t years; male, 
67.9%) enrolled in the study. Median (interquartile range [IQR]) baseline CD4 was 
31 (14~9) cells/mm 3 and HIV-1 RNA count was 433,500 (169,000~50,000) copies/mL. 
At week 96, 87 patients (ITT, 62.1%; OT, 87.0%) achieved HIV-1 RNA <50 copies/mL. 
Median (IQR) CD4 at 96 weeks was 328 (229 450) cells/mm 3.The reasons for drug 
discontinuation were as follows: drug resistance (9.3%), lost to follow-up (9.3%), NVP- 
related rashes (7.9%), death (5.0%), d4T-related adverse vents (3.6%), and transferred to 
another hospital (2.1%). At 96 weeks, 25 patients (28.7%) had low-density lipoprotein 
cholesterol (LDL-C) >130 mg/dL, 7 (8.0%) had LDL-C >160 mg/dL, 6 (6.9%) had tri- 
glycerides >400 mg/dL, and 2 (2.3%) had FPG >126 mg/dL. Eleven patients (12.6%) 
had a lactic acid level >2.5 mmol/L. Eight patients (9.2%) needed to take antihypertensive 
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agents. Of 13 patients who developed virologic failure, 76.9% and 61.5% had M184V/I 
and Y181C/I mutations, respectively. 
CONCLUSIONS:  Initiation of this FDC ofd4T/3TC/NVP in these ART-naive patients 
with advanced HIV infection and low baseline CD4 cell count was effective at 96 weeks 
of follow-up with regard to virologic and immunologic responses. However, long-term 
metabolic omplications, particularly dyslipidemia, were common and should be closely 
monitored. (Curr Ther Res Clin Exp. 2008;69:90 100) © 2008 Excerpta Medica Inc. 
KEY WORDS:  HIV, effectiveness, metabolic, GPOvir-S, nevirapine. 
INTRODUCTION 
The public health approach to antiretroviral therapy (ART) scale-up in resource- 
limited situations aims to support he development of treatment programs that can reach 
as many patients as possible. One of the keys to this approach is standardization a d 
simplification of treatment regimens. Currently, nonnucleoside r verse transcriptase 
inhibitor (NNRTI)-based highly active ART (HAART) is an optional recommended 
regimen as an initial therapy for treatment-naive HIV-infected patients. 1,2 In addi- 
tion, current ART guidelines I for HIV infection in adults and adolescents in the 
resource-limited settings recommend using 2 nucleoside reverse transcriptase inhibi- 
tors (NRTIs) plus 1 NNRTI  as the first-line antiretroviral regimen. 3 Regimens based 
on these combinations are efficacious, low pill burden, less expensive, generic formu- 
lations, and are available as fixed-dose combinations (FDCs). 4 This can preserve the 
protease inhibitor (PI) for future options and delay patient exposure to some adverse 
events (AEs) associated with PI drugs. Two NNRTIs are currently available for clini- 
cal use in the treatment of HIV disease. Nevirapine and efavirenz have been associat- 
ed with antiretroviral effectiveness. 3,5,6 A 48-week, randomized, open-label trial in 
1216 ART-naive patients found that both drugs had similar antiviral effectiveness. 3 
Treatment failure occurred in 96 of 220 patients (43.6%) assigned nevirapine QD, 
169 of 387 (43.7%) assigned nevirapine BID, 151 of 400 (37.8%) assigned efavirenz, 
and 111 of 209 (53.1%) assigned nevirapine plus efavirenz. At week 48, there were 
no significant differences among the study groups in the proportions with plasma 
HIV-1 RNA concentrations < 50 copies/mL or increases in CD4 ceils. 
Since 2002, the Thai Government Pharmaceutical Organization (GPO), Bangkok, 
Thailand, has produced an FDC (GPOvir-S ®) of 30- or 40-mg stavudine (d4T), 
150-mg lamivudine (3TC), and 200-mg nevirapine (NVP). This combination formula 
(d4T/3TC/NVP) is administered as 1 tablet BID and facilitates adrug supply procedure 
for the national ART program. A previous pilot study 7 of bioequivalence found that 
NVP concentrations were above the recommended minimum (>3100 ng/mL). In a 
cohort of 6861 adult patients who initiated treatment with d4T/3TC/NVP, analysis of 
results determined effectiveness and tolerability of generic FDC in preventing AIDS- 
related mortality in resource-limited settings. 8 
There are some potential limitations of NVP-based ART including AEs, low genetic 
barrier (single mutation can confer drug resistance), cross-resistance within this drug 
class, and prevalence of NRTI-resistant viral strains in ART-naive HIV-infected pa- 
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tients. 2Skin rash is the most frequently observed AE (17%) associated with NVE The 
risk of rash at any severity is greatest in the first 6 weeks. 9d4T-Associated metabolic om- 
plications include lactic acidosis, dyslipidemia, morphological changes, and dysregulation 
of glucose metabolism. 1° Symptomatic lactic acidosis is a rare (0.5 1/100 patient-years) 
but life-threatening complication due to prolonged NRTI administration, particularly 
d4T. Peripheral polyneuropathy is primarily associated with d4T and didanosine dide- 
oxyinosine. 2 It usually presents with a distal symmetrical distribution and sensorimotor 
paralysis. 
FDC ART has an advantage in terms of lower number of pills and cost. In Thailand, 
the cost of this regimen is approximately US $40 per month. These advantages are 
major reasons for successful ART scale-up in Thailand. However, one major concern 
regarding the use of generic FDC ART in the developing countries is its effectiveness. 
A search of the Thai-language literature of MEDLINE using the term GPO-vir found 
a number of published studies 11 15 regarding short-term effectiveness in Thais. In a 
24-week, open-label, single-arm trial by Anekthananon et al, 11 patients administered 
generic d4T/3TC/NVP had a mean (SD) increase in CD4 cell count of 96.5 (63.5) cells/ 
mm 3 (P < 0.001 vs baseline). The study by Kiertiburanakul et a112 found that in a 
median follow-up of 15 weeks, 49 of 90 patients (54%) administered 4T/3TC/NVP 
achieved the goal of HIV RNA <50 copies/mL or >50% increased in CD4 cell count. 
Tin et a113 found that, in 83 ART-naive patients with HIV infection, CD4 counts 
increased by a median of 78 x 106 cells/L during the first 3 months of treatment. After 
2 years of treatment, 39.5% of the patients attained median CD4 counts >200 x 106 cells/L. 
A retrospective cohort study 14 conducted in ART-naive HIV-infected patients initiated 
on d4T/3TC/NVP found that there was no difference between patients with CD4 cell 
count <50 cells/mm 3 and those with >50 cells/mm 3 in terms of tolerability and effec- 
tiveness. In a 48-week, open-label, combined prospective and retrospective study 15 
involving 102 HIV-infected patients with baseline CD4 cell count <100 cells/mm 3, the 
median CD4 cell count increased to 191 cells/mm 3.
Nonetheless, the long-term data regarding effectiveness and metabolic omplications 
of d4T/3TC/NVP among advanced HIV-infected patients with low CD4 are still limit- 
ed. Therefore, we conducted a prospective study to determine long-term immunologic 
and virologic outcomes and long-term metabolic events of d4T/3TC/NVP in HIV- 
infected patients who had baseline CD4 cell counts <250 cells/mm 3.
PAT IENTS AND METHODS 
The institutional ethics committees of the Bamrasnaradura Infectious Diseases Insti- 
tute and the Ministry of Public Health, Nonthaburi, Thailand, approved the study. 
All patients provided written informed consent prior to study enrollment. 
STUDY DES IGN 
A prospective study was conducted among ART-naive HIV-infected patients who 
were initiated on d4T/3TC/NVP between November 2004 and March 2005 at the 
Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health. Inclusion 
criteria were as follows: (1) HIV-infected individuals >15 years old; (2) naive to ART 
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prior to d4T/3TC/NVP; (3) baseline CD4 cell counts <250 cells/mm3; (4) initiated with 
a d4T/3TC/NVP; and (5) willing to participate and sign informed consent. Exclusion 
criteria were: (1) baseline serum creatinine level >2.0 mg/mL; (2) baseline alanine ami- 
notransferase (ALT) >5 times the upper limit of normal; and (3) pregnancy. All patients 
were administered a separate NVP 200 mg QD lead-in dose during the first 2 weeks, 
prior to escalation to 200 mg BID. The patients received 4T 40 mg BID if body weight 
was >60/kg. In the presence of toxicity, the of/ending drug was substituted with second- 
line drugs; efavirenz was substituted for NVP and zidovudine was substituted for d4T. 
All patients were visited every 6 weeks to monitor clinical response and AEs as standard 
of care in our institute. The final decision regarding whether the relevant AEs were 
associated with study drug administration was made by the attending investigator. 
All patients were followed-up for a total of 96 weeks after initiation of d4T/3TC/NVE 
CD4 cell count, plasma HIV-1 RNA, and ALT enzyme were assessed at baseline, and 
after 12, 24, 36, 48, 60, 72, 84, and 96 weeks of ART. Total cholesterol, low-density 
lipoprotein cholesterol (LDL-C), triglycerides, and fasting plasma glucose (FPG) were 
assessed after 96 weeks of ART. The primary outcome of interest was the proportion 
of patients who achieved plasma HIV-1 RNA < 50 copies/mL after 96 weeks of ART 
analyzed by intent-to-treat (ITT) and on-treatment (OT) groups. The ITT population 
included enrolled patients who received >1 dose of ART. OT analysis included all 
patients who completed 96 weeks of ART. The secondary outcomes were as follows: 
(1) change from baseline in CD4 cell count after 96 weeks of ART; (2) incidences 
of NVP-associated AEs including skin rashes and hepatotoxicity; (3) incidence of 
d4T-associated symptomatic lactic acidosis that led to discontinuation of d4T and 
serum lactic acid level of patients who continued 4T after 96 weeks; (4) proportion 
of patients who developed abnormal FPG or serum lipid levels and needed to com- 
mence antihypertensive agents; and (5) genotypic drug-resistance pattern after virologic 
failure. 
The severity of skin rashes was determined using the AIDS Clinical Trial Group toxici- 
ties scale 16 as follows: Level I, erythema; Level II, diftuse maculopapular rash or urticaria; 
Level III, rash with constitutional symptoms, angioedema, serum sickness-like reactions, 
or Stevens-Johnson syndrome; and Level IV, toxic epidermal necrolysis. The patients' com- 
pliance was assessed by pill count at each visit and self-report. Noncompliance was defined 
by missing doses of >80% in the previous 4 weeks. In the case of noncompliance, patients 
were educated to improve the adherence to treatment. 
CD4 cell counts were measured by flow cytometry. All of the plasma samples were 
analyzed for HIV-1 RNA using reverse transcription-polymerase chain reaction (COBAS 
AMPLICOR HIV-1 monitor version 1.5, Roche Diagnostics GmbH, Mannheim, 
Germany), according to the manufacturer's instructions. HIV-1 RNA levels were 
expressed as copy number per mL of plasma, and the lower detection limit of the assay 
was 50 copies/mL. Plasma samples were separated from the cell fraction by centrifuga- 
tion at 700g for 10 minutes and then frozen at 70°C until tested for HIV-1 RNA. 
Virologic failure was defined as either a rebound plasma HIV-1 RNA of >1000 copies/mL 
after having a previously undetectable value, or lack of achievement to <50 copies/mL 
at 24 weeks of ART. Genotypic resistance testing was performed after the patient was 
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documented tohave virologic failure. HIV-1 RNA was extracted from plasma samples, 
using a viral extraction kit (QIAamp, Qiagen Inc., Chatsworth, California). A genotyp- 
ing assay (TruGene HIV-1, Visible Genetics Inc., Toronto, Canada) was used in conjunc- 
tion with an automated DNA sequencing system (OpenGene, Visible Genetics Inc.) to 
sequence the protease and reverse transcriptase (RT) regions of the HIV-1 complemen- 
tary DNA. 
Blood samples used to measure lactate were collected at rest >15 minutes prior to 
phlebotomy with no use of tourniquets and no fist clenching while blood was drawn. 
The samples were kept in fluoride tubes to prevent further lactate production and were 
rapidly delivered to the test laboratory on ice. Analysis was conducted using a bench-top 
analyzer (COBAS INTEGRA 400, Roche Diagnostics Corp., Indianapolis, Indiana). 
STAT IST ICAL  ANALYSES 
Mean (SD), median (interquartile range), and frequencies (%) were used to de- 
scribe patients' characteristics. The proportion of patients with plasma HIV-1 RNA 
< 50 copies/mL after 96 weeks of ART were analyzed as ITT and OT populations. 
Missing data on plasma HIV-1 RNA levels were taken to be >50 copies/mL. Pa- 
tients experiencing AEs, or anything that might have led to change, modification, 
or discontinuation of the regimen, were excluded from the final analysis at week 96. 
Cox regression analysis was used to determine risk ratio. Statistical calculations 
were performed using SPSS version 11.5 (SPSS Inc., Chicago, Illinois). A 2-sided P < 
0.05 was considered statistically significant. 
RESULTS 
There were 140 patients (mean [SD] age, 35.7 [7.6] years; male, 67.9%) enrolled in 
the study. Baseline characteristics of the patients are shown in Table I. Six patients 
did not meet inclusion criteria. One hundred patients were still receiving treatment 
after 96 weeks of follow-up. At week 96, 87 patients (ITT, 62.1%; OT, 87.0%) 
achieved HIV-1 RNA < 50 copies/mL. The percentage ofpatients who achieved un- 
detectable plasma HIV-1 RNA <50 copies/mL and CD4 cell count response at each 
study time point are shown in Figures 1 and 2, respectively. At 12, 24, 36, 48, 60, 
72, 84, and 96 weeks, median CD4 cell counts were 142, 182,223,234,  254, 321, 
322, and 328 cells/mm 3, respectively. By Cox regression analysis, HIV-infected patients 
who had plasma HIV-1 RNA at 12 weeks >400 copies/mL were 17 times more likely 
to have virologic failure after 96 weeks of ART (P 0.001), as shown in Table II. 
The reasons for drug discontinuation were as follows: drug resistance (13 patients 
[9.3%]); lost to follow-up (13 [9.3%]); NVP-related skin rashes, grades II and III (11 
[7.9%]); death (7 [5.0%]); d4T-related neuropathy (4 [2.9%]); transferred to another 
hospital (3 [2.1%]); and symptomatic lactic acidosis (2 [1.4%]). All NVP-related skin 
rashes developed within the first 12 weeks after initiation of ART. At 12 weeks after 
ART, 5 of 121 patients (4.1%) developed ALT >3 times the upper limit of normal. None 
of the patients developed clinical hepatitis. All causes of death were deemed not to be 
related to study drugs. During the study period, 30 patients (21.4%) in this cohort 
needed to change to other regimens. 
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Table I. Baseline demographic and clinical characteristics of antiretroviral therapy-naive 
HIV-infected patients in Thailand (N = 140). 
Characteristic Value 
Age, mean (SD), y 
Male sex, no. (%) 
Weight, mean (SD), kg 
CD4 cell count, median (IQR), cells/mm 3 
CD4 percentage, median (IQR) 
Plasma HIV RNA, median (IQR), copies/mL 
Alkaline phosphatase, median (IQR), U/I 
Alanine transaminase, median (IQR), U/I 
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Figure 1. Percentage of antiretroviral therapy (ART)-naive advanced HIV-infected 
patients (both intent-to-treat [ITT] and on-treatment [OT] populations) in 
Thailand who achieved undetectable plasma HIV-1 RNA <50 copies/mL after 
administration of a generic fixed-dose combination of stavudine, lamivudine, 
and nevirapine for 96 weeks. 
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Figure 2. Immunologic outcomes after 96 weeks of antiretroviral therapy (ART) with 
a generic fixed-dose combination of stavudine, lamivudine, and nevirapine in 
ART-naive advanced HIV-infected patients in Thailand. 
At 96 weeks, 54 icyatients (62.1%) tzad total cholesterol >200 mg/dI,, 25 (28.7%) had LDL-C 
>130 mg/dL, 7 (8.0%) had LDL-C >160 mg/dL, 6 (6.9%) had triglycerides >400 mg/dL, 
and 2 (2.3%) had FPG >126 mg/dL, respectively. Eleven patients (12.6%) had lactic acid 
levels >2.5 mmol/L; all 11 were asymptomadc hyperlactatemia. Eight patients (9.2%) 
needed to commence antihypertensives. No risk factor was found to be associated with 
total cholesterol >200 mg/dL after adjusting for age, sex, and baseline weight. 
Table II. Cox regression of possible risk factors for achieving undetectable plasma HIV-RNA 
<50 copies/mL after 96 weeks of antiretroviral therapy in ART-naive HIV-infected 
patients in Thailand (N = 140).  
Risk Factor HR 95% CI P 
Plasma HIV-RNA 
_>400 cop ies /mL at 12 weeks 17.241 3 .067-100 .000  0.001 
Age 0.961 0 .878-1 .052  0 .389 
Sex 1.024 0 .229-4 .580  0.976 
Weight 1.015 0 .937-1 .099  0.720 
Baseline CD4 cell counts 1 .006 0 .994-1 .019  0.312 
Baseline log plasma HIV-RNA 1.775 0 .466-6 .757  0 .400 
HR = hazard ratio. 
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Among the 13 patients with drug resistance, 5 (38.5%) had mutations contributing 
to NRTI resistance, 1 (7.7%) had NNRTI  resistance, and 7 (53.8%) had both NRTI and 
NNRTI  resistance. Of the NRTI-resistant mutations, M184V/I was the most common 
(10 [76.9%]). Thymidine analog associated mutations (TAMs) were found in 1 patient 
(7.7%). K65R was observed in 2 patients (15.4%). For NNRTI-resistant mutations, there 
were Y181C/I (8 [61.5%]) and K103N (1 [7.7%]). 
DISCUSSION 
The results from the present study suggest hat a generic FDC, d4T/3TC/NVP, had 
favorable long-term effectiveness for >96 weeks. Approximately 62% of patients 
achieved undetectable plasma HIV-1 RNA <50 copies/mL by ITT analysis. When 
compared with 65.4% (253/387) of patients who achieved undetectable plasma 
HIV-1 RNA at 48 weeks in a prospective comparative study, 3the antiviral effective- 
ness of d4T/3TC/NVP appears atisfactory. 
In the resource-limited countries, including Thailand, HIV-infected patients usually 
present late with very low CD4 cell counts. 17 Although a significant proportion of 
patients (75%) in the present study had baseline CD4 cell counts of <80 cells/mm 3,
there was a marked increase of CD4 ceils after 96 weeks. The increment was not 
blunted by the very low baseline CD4 cell counts. Overall, the virologic and immunologic 
effectiveness was consistant with that reported from ART in the developed countries. 3 
The well-established predictors of long-term virologic success include potency of ART 
regimen, adherence totreatment, low baseline viremia, higher baseline CD4 cell counts, 
and rapid reduction of viremia in response to treatment. 18'19 In the present study, 
patients who still had plasma HIV-1 RNA levels at week 12 of >400 copies/mL were 
17 times more likely to have diagnosed virologic failure by multivariate analysis. A pro- 
spective observational cohort study conducted in Barbados in 158 antiretroviral-naive 
HIV patients also demonstrated that there was a high rate of virologic and immunologic 
success (123 patients [78%] achieved viral loads of <50 copies/mL) after 6 months of 
HAART, irrespective of the pre-HAART viral load and CD4 cell count. 2° Therefore, 
baseline CD4 cell counts was not a predictive factor of virologic failure. 
Regarding the short-term AEs, all were attributed to NVR Despite receiving 2 weeks 
of NVP 200-mg QD lead-in dose prior to escalation to 200 mg BID, -8% of patients 
had developed NVP-associated skin rashes (grade II III) that led to NVP discontinu- 
ation. All of these patients tolerated efavirenz well. Previous tudies 3,21 found that NVP 
may cause a mild skin rash in 15% to 20% of patients, 5% to 10% of whom discontin- 
ued treatment. This rate is similar to that observed in the previous tudies in Thais. 11,22 
Our recent study 23 reported 1.2-fold greater chance of developing NVP-associated skin 
rashes in every increment of baseline CD4 50 cell counts of cells/mm 3.
Long-term administration of NRTI, particularly d4T, can cause mitochondrial tox- 
icity. 2 The clinical manifestations of this AE present as hyperlactatemia and polyneu- 
ropathy. 24 In the present study, d4T-related neuropathy and/or symptomatic lactic aci- 
dosis was observed in 4 (2.9%) and 2 (1.4%) patients, respectively, after 96 weeks of 
treatment. Although this number is relatively low, this well-established AE should be 
closely monitored in long-term treatment. In addition, prolonged administration ofd4T 
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is associated with increased triglycerides and cholesterol. 2 Routine monitoring of lipid 
levels should be assessed among the patients who receive this drug. 2 Currently, d4T is 
not a first-line antiretroviral drug recommended in the recent developed country guide- 
lines due to its significant toxicities. 25 The role of d4T as a preferred companion NRTI 
drug should be reconsidered in future revised treatment guidelines in the resource- 
limited settings including Thailand. NRTIs with less toxicity should be considered as 
substitutions for d4T in the core regimen. 
Another concern is the emergence of drug resistance due to the low genetic barrier 
of NVP and 3TC in the regimen. The most common changes elected by NVP involve 
a K103N mutation and a Y181C/I mutation. 26 The present study found that almost all 
of NVP-associated mutation was Y181C/I. Eight percent had K103N while >60% had 
Y181C/I. Resistance to 3TC is conferred by a point mutation at RT codon 184, produc- 
ing M184V or M184I. 27,28 Therefore, it is not surprising that -77% of the patients had 
M184V/I. The options of a second-line regimen are still available for these patients, 
based on a low rate of TAMs; zidovudine plus didanosine and zidovudine plus tenofovir 
would be available options. In the present study, plasma HIV-1 RNA was assessed every 
12 weeks through 96 weeks of ART. However, with regard to real-life clinical practice 
in resource-limited situations, plasma HIV-1 RNA might not be regularly performed 
every 12 weeks as in this study. 
Our findings may support he prescribing of d4T/3TC/NVP to patients in resource- 
limited settings. However, d4T-associated long-term metabolic omplications, particu- 
larly dyslipidemia nd lactic acidosis, are common and should be closely monitored. 
Strategy to minimize long-term toxicity of d4T/3TC/NVP, such as switching to other 
ART combinations at an optimal time, should be evaluated. 
L IMITAT IONS 
The study design was not comparative, which might have been essential to evaluat- 
ing the eflbctiveness ofan antiretroviral regimen. The study also was not blinded and AEs 
were not monitored. Though the sample size was relatively small, results of the present 
study may provide useful clinical data for the care of advanced HIV-infected patients 
in developing countries. Baseline hepatitis B, hepatitis C serology, baseline lipid profile, 
and FPG were not performed prior to ART initiation. Thus, the actual proportion of 
patients who developed metabolic omplications may not be accurate. However, the 
high number of cases (4 d4T-related neuropathy and 2 symptomatic hyperlactatemia) in 
this study may reflect some degree of this complication. Lastly, lactate measurement 
was not repeatedly performed at each time point. However, we perform this laboratory 
test within the 15-minute rest period prior to phlebotomy, without the use of tourni- 
quets and fist clenching. Therefore, we consider the lactate level from a single lactate 
measurement to be reliable. 
CONCLUSIONS 
Initiation of this FDC of d4T/3TC/NVP in these ART-naive patients with advanced 
HIV infection and low baseline CD4 cell count was effective at 96 weeks of follow- 
up with regard to virologic and immunologic responses. However, long-term meta- 
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bolic complications, particularly dyslipidemia, were common and should be closely 
monitored. 
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